WebHeadquarters Parsippany, New Jersey Type Privately Held Specialties Antimicrobials, Antibiotics, and Acute Care Locations Primary 389 Interpace Pkwy Suite 450 Parsippany, New Jersey 07054, US Get... Web20 apr. 2024 · CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 20, 2024 MELINTA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Registrant’s telephone number, including area code (908) 617-1309
Melinta Therapeutics Company Profile: Funding & Investors
Web28 nov. 2024 · 149 articles with Melinta Therapeutics. Melinta Therapeutics & OptimizeRx Announce 2024 Innovate4Outcomes Event. 11/30/2024. Melinta Therapeutics, LLC, a commercial-stage company providing innovative patient care therapies for acute and life-threatening illnesses, is partnering with OptimizeRx Corp. in an Innovate4Outcomes … Web9 aug. 2024 · Company Contacts: John Bluth Cempra, Inc. (984) 209-4534 [email protected] Lyn Baranowski Melinta Therapeutics, Inc. (203) 848-3346 [email protected] Media Contact: Melyssa Weible Elixir Health PR ... olive tree day nursery and preschool
Document - SEC
Web27 dec. 2024 · Item 1.03 Bankruptcy or Receivership. As previously disclosed, on December 27, 2024, Melinta Therapeutics, Inc. (the "Company") and its debtor affiliates (together with the Company, the "Debtors") filed voluntary petitions for relief (the "Chapter 11 Case") under chapter 11 of title 11 of the United States Code (the "Bankruptcy Code") in the United … Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital and community settings. The company is located in New Haven, Connecticut. In mid-2011, Sanofi entered into a global research collaboration and licensing option with the co… Web15 mrt. 2024 · Melinta Therapeutics Announces FDA Approval of KIMYRSA™ (oritavancin) for the Treatment of Adult Patients with ABSSSI. Contacts Susan Blum (312) 767-0296 [email protected] olive tree cottage aylesbeare